KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Capital Expenditures (2016 - 2025)

Neogenomics' Capital Expenditures history spans 16 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 127.67% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $27.0 million, up 2568.77%, while the annual FY2025 figure was $27.0 million, 2568.77% up from the prior year.
  • Capital Expenditures reached $7.9 million in Q4 2025 per NEO's latest filing, down from $8.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $48.3 million in Q3 2021 to a low of -$50.8 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $4.4 million, with a median of $6.0 million recorded in 2024.
  • Peak YoY movement for Capital Expenditures: soared 758.51% in 2021, then plummeted 954.46% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$50.8 million in 2021, then soared by 108.92% to $4.5 million in 2022, then skyrocketed by 55.65% to $7.1 million in 2023, then tumbled by 503.15% to -$28.4 million in 2024, then surged by 127.67% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Capital Expenditures are $7.9 million (Q4 2025), $8.3 million (Q3 2025), and $6.3 million (Q2 2025).